Package Leaflet: Information for the User
Rivaroxaban Vir 10 mg Film-Coated Tablets EFG
Read the entire package leaflet carefully before starting to use this medication, as it contains important information for you.
Contents of the Package Leaflet
Rivaroxaban Vir contains the active substance rivaroxaban and is used in adults for:
Rivaroxaban belongs to a group of medications called antithrombotic agents. It works by blocking a clotting factor (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Rivaroxaban Vir
Do not take Rivaroxaban Vir and inform your doctorif any of these circumstances apply to you.
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Rivaroxaban.
Be careful with Rivaroxaban Vir
Tell your doctorif you have any of these situationsbefore taking rivaroxaban. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery:
Children and Adolescents
Rivaroxaban is not recommended for children under 18 years of age. There is not enough information about its use in children and adolescents.
Other medications and Rivaroxaban Vir
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those purchased without a prescription.
other medications to reduce blood clotting (e.g., enoxaparin, clopidogrel, or vitamin K antagonists, such as warfarin or acenocoumarol)
If any of the above circumstances apply to you,tell your doctorbefore taking rivaroxaban, as the effect of rivaroxaban may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing stomach or intestinal ulcers, they will recommend that you also use an ulcer prevention treatment.
If any of the above circumstances apply to you,tell your doctorbefore taking rivaroxaban, as the effect of rivaroxaban may be reduced. Your doctor will decide if you should be treated with rivaroxaban and if you should be kept under closer observation.
Pregnancy and Breastfeeding
Do not take rivaroxaban if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking rivaroxaban. If you become pregnant while taking this medication, tell your doctor immediately, who will decide how you should be treated.
Driving and Using Machines
Rivaroxaban may cause dizziness (a frequent side effect) or fainting (a rare side effect) (see section 4, "Possible side effects"). You should not drive or use machines if you are affected by these symptoms.
This medication contains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow the administration instructions of this medication exactly as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
What doseto take
The recommended dose is one 10 mg rivaroxaban tablet once a day.
After at least 6 months of treatment for blood clots, the recommended dose is one 10 mg tablet once a day or one 20 mg tablet once a day. Your doctor has prescribed rivaroxaban 10 mg once a day.
Swallow the tablet, preferably with water.
Rivaroxaban can be taken with or without food.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take rivaroxaban. The tablet can be crushed and mixed with water or apple sauce, immediately before taking it.
If necessary, your doctor can also administer the crushed rivaroxaban tablet through a gastric tube.
When to take Rivaroxaban Vir
Take one tablet every day, until your doctor tells you to stop.
Try to take one tablet at the same time every day, to help you remember.
Your doctor will decide how long you should continue treatment.
To prevent the formation of blood clots in the veins after hip or knee replacement surgery:
Take the first tablet 6 to 10 hours after surgery.
If you have undergone major hip surgery, you will usually take tablets for 5 weeks.
If you have undergone major knee surgery, you will usually take tablets for 2 weeks.
If you take more Rivaroxaban Vir than you should
Call your doctor immediately if you have taken too many rivaroxaban tablets. Taking too much rivaroxaban increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount taken.
If you forget to take Rivaroxaban Vir
If you forget to take a dose, take it as soon as you remember. Take the next tablet the next day and, after that, take one tablet every day, as usual.
Do not take a double dose to make up for forgotten doses.
If you stop taking Rivaroxaban Vir
Do not stop taking rivaroxaban without talking to your doctor first, as rivaroxaban prevents the development of a serious condition.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Like other similar medications to reduce blood clotting, rivaroxaban may cause bleeding, which can be life-threatening. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be apparent.
Possible side effects that may be signs of bleeding:
Tell your doctor immediately if you experience any of the following side effects:
Your doctor will decide to keep you under closer observation or modify your treatment.
The frequency of these side effects is very rare (affecting up to 1 in 10,000 people).
The frequency of severe allergic reactions is very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible side effects:
Common(may affect up to 1 in 10 patients):
Uncommon(may affect up to 1 in 100 patients):
Rare(may affect up to 1 in 1,000 patients):
Frequency not known(cannot be estimated from available data):
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and on each blister, after "CAD" or "EXP". The expiration date is the last day of the month indicated.
No special storage conditions are required.
Crushed tablets
Crushed tablets are stable in water or apple sauce for up to 4 hours.
Medications should not be thrown down the drain or into the trash. Deposit the packaging and medications you no longer need in the SIGRE Point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Rivaroxaban Vir Composition
Tablet core: microcrystalline cellulose, lactose monohydrate, hypromellose (2910), sodium croscarmellose, magnesium stearate, sodium lauryl sulfate.
Tablet film coating: hypromellose (2910), macrogol (3350), titanium dioxide (E 171), red iron oxide (E 172).
Rivaroxaban Vir 10 mg film-coated tablets are pink, round, biconvex (6 mm in diameter) tablets marked with "10" on one side and smooth on the other side.
Packaging containing 10, 14, 30, 35, or 100 film-coated tablets in transparent PVC/PVDC-Aluminum blisters.
Only some package sizes may be marketed.
Industria Química y Farmacéutica VIR, S.A.
C/Laguna 66-68-70. Polígono Industrial Urtinsa II
28923 Alcorcón (Madrid)
Spain
Saneca Pharmaceuticals a.s.
Nitrianska 100
920 27 Hlohovec
Slovak Republic
or
Adalvo Limited
Malta Life Sciences Park, Building 1,
Level 4, Sir Temi Zammit Buildings,
San Gwann
SGN 3000, Malta
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/